Sharon Ayd

Dr. Sharon Ayd is a biopharmaceutical industry veteran with greater than 30 years of experience in commercializing Branded/Novel, Specialty, Rare/Orphan, and Complex Generic drugs. Drug product types include small molecules as well as biologics. She has a record of value creation for companies, as demonstrated by having led numerous international drug development programs from translation/discovery through clinical evaluation, the regulatory review and approval process, product launch, and lifecycle management. During her career Dr. Ayd has worked in several multinational companies, including Baxter International, Apotex Inc., Hospira (now Pfizer), and Fresenius-Kabi. She has also been a founding/C-level executive in start-ups, e.g., Transcend Therapeutics, Advanced Life Sciences, and Pinnacle Biologics. Under her leadership ~100 drug application approvals (NDA, 505(b)(2), ANDA, and biosimilar and supplements) have been obtained. She has also been a key player in many M&A transactions, ranging from $200M to ~$1B. In 2014 Dr. Ayd formed her own consultancy, Ayd BioPharma Consulting Group. The Ayd Group serves clients in Life Sciences, Pharmaceuticals, Biologics, and Combination Products. She is Adjunct Professor at the University of Illinois College of Pharmacy and the Northwestern University Pritzker School of Law. Dr. Ayd earned an MBA from Lewis University and a PhD from the University of Illinois at Chicago in Biopharmaceutical Sciences.